Tagged with R

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you the seven biggest biotech IPOs this year. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market. Made with Visme Infographic Maker

Singapore Singapore is home to a wide range of biopharmaceutical company headquarters, many of them regional bases, and clusters. Made with Visme Infographic Maker   Singaporean pharma exports are projected to grow rapidly year-on-year up to 2024. Made with Visme Infographic Maker  

Singapore Singapore is far ahead of its Asia-Pacific peers in terms of GDP per person. Made with Visme Infographic Maker   Singapore was ranked Asia-Pacific’s, and indeed the world’s, most competitive country/region for 2019. Made with Visme Infographic Maker   Singapore also performs well on the world digital ranking, sitting behind only the…

China PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established in 2012, the company introduced the novel DEL technology platform to China.   As Dr Li recounted, “it was not…

Global Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and Harvard universities, as well as helping coordinate the WHO’s response to the West African Ebola virus epidemic of 2013-2016 and being the founding CEO of the Coalition for Epidemic…

Norway CEO Ellen Cathrine Andersen introduces Norwegian firm Epiguard’s ‘Epishuttle’ technology for transporting highly contagious patients, the crucial role that the product is playing in helping to tackle the COVID-19 pandemic across the world, and where she hopes to take the company moving forward.   We have now sold the Epishuttle…

Norway Dennis Hens, the Dutch CEO of Norwegian neuro-opthalmology device player Bulbitech, outlines the company’s journey to market, how its technology can support both optometrists and neurologists in their work, and gives an overview of the investment landscape for innovative medtech in Norway.   Norway is a very good country to…

Global Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest initial investment in Sanofi’s COVID-19 vaccine development, should have the first call on any vaccine that the firm was subsequently able to bring to market. In…

Global During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger Connor shared some of his insights regarding the reorganization of GSK’s Consumer Health, Pharmaceuticals and Vaccines business units, their pandemic adjuvant system technology, and their – and the industry’s overall – commitment to COVID-19 vaccine…

Global Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global Pharmaceutical and Biotechnology Conference last week and explained how the industry should take on a wider and deeper role in shaping healthcare systems, thereby creating…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving the evolution of the pharma innovation model. The session was moderated by Deloitte global life sciences and health care leader…

Canada Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact of COVID-19, and where the field is headed for the future.   The cannabis plant has been used as a…